Business Context and Reporting Period
This Form 8-K was filed by Trovagene, Inc. (not Cardiff Oncology, Inc.) on November 28, 2016. The report covers a specific event occurring on the same date regarding the company's Precision Cancer Monitoring (PCM) technology.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a scientific/operational event rather than financial performance.
Material Changes
The company announced that its PCM technology for urine and plasma EGFR mutation testing demonstrated significantly greater detection sensitivity compared to tissue testing alone.
Guidance, Outlook, and Risks
Management highlighted the superior sensitivity of their non-invasive testing method. The filing does not contain specific financial guidance, risk factors, or contingencies beyond the general context of the technology announcement.
Investor Verification Checklist
- Verify the registrant name is Trovagene, Inc., not Cardiff Oncology, Inc.
- Review the attached press release (Exhibit 99.1) for detailed clinical data supporting the sensitivity claims.
- Confirm the regulatory status and commercialization timeline for the PCM technology.
- Check subsequent filings for any financial impact resulting from this technology advancement.